Key result
Rivaroxaban successfully treated deep vein thrombosis in a patient receiving concurrent platinum-based chemotherapy without interrupting the chemotherapy schedule.
Why the study?
Deep vein thrombosis is a common treatment-related complication following surgery and chemotherapy, prompting the need to report management that does not interrupt cytotoxic treatment schedules.
Case Report (n=1)
No
This case report demonstrates that rivaroxaban can effectively treat deep vein thrombosis in a patient receiving platinum-based chemotherapy without requiring daily subcutaneous injections or interrupting the chemotherapy schedule.
May support oral rivaroxaban for DVT during platinum chemotherapy; leaves open confirmation in prospective trials.
Deep Vein Thrombosis (DVT) is a common treatment-related complication following surgery and chemotherapy. We are reporting a case of colorectal cancer-associated thrombosis during platinum-based chemotherapy. The patient was treated with Rivaroxaban (Xarelto), a highly selective direct Factor Xa inhibitor. This case report highlights the concurrent use of novel oral anticoagulants, which does not interrupt the chemotherapy schedule among patients receiving cytotoxic agents.
No takes yet. Share an insight, caveat, or question.
Gunasekaran et al. (2021) conducted a case report in Deep vein thrombosis associated with colorectal cancer during platinum-based chemotherapy (n=1). Rivaroxaban was evaluated on Resolution of deep vein thrombosis. Rivaroxaban successfully treated deep vein thrombosis in a patient receiving concurrent platinum-based chemotherapy without interrupting the chemotherapy schedule.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: